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Although CD90 has been identified as a marker for various
kinds of stem cells including liver cancer stem cells
(CSCs) that are responsible for tumorigenesis, the poten-
tial role of CD90 as a marker for CSCs in gliomas has not
been characterized. To address the issue, we investigated
the expression of CD90 in tissue microarrays containing
15 glioblastoma multiformes (GBMs), 19 WHO grade III
astrocytomas, 13 WHO grade II astrocytomas, 3 WHO
grade I astrocytomas and 8 normal brain tissues. Immu-
nohistochemical analysis showed that CD90 was ex-
pressed at a medium to high level in all tested high-grade
gliomas (grade III and GBM) whereas it was barely detect-
able in low-grade gliomas (grade I and grade II) and nor-
mal brains. Double immunofluorescence staining for
CD90 and CD133 in GBM tissues revealed that CD133
CSCs are a subpopulation of CD90 cells in GBMs in vivo.
Flow cytometry analysis of the expression of CD90 and
CD133 in GBM-derived stem-like neurospheres further
confirmed the conclusion in vitro. The expression levels of
both CD90 and CD133 were reduced along with the loss of
stem cells after differentiation. Furthermore, the limiting
dilution assay demonstrated that the sphere formation
ability was comparable between the CD90/CD133 and
the CD90/CD133 populations of GBM neurospheres,
which is much higher than that of the CD90/CD133
population. We also performed double staining for CD90
and a vascular endothelial cell marker CD31 in tissue
microarrays which revealed that the CD90 cells were
clustered around the tumor vasculatures in high-grade
glioma tissues. These findings suggest that CD90 is not
only a potential prognostic marker for high-grade gliomas
but also a marker for CSCs within gliomas, and it resides
within endothelial niche and may also play a critical role in
the generation of tumor vasculatures via differentiation
into endothelial cells. Molecular & Cellular Proteomics
11: 10.1074/mcp.M111.010744, 1–8, 2012.
Gliomas constitute the majority of primary brain tumors.
The most common kind of glioma are astrocytomas which are
further classified into four grades by the WHO-grading
scheme. WHO grade I and II are well differentiated and con-
sidered as low grade, while WHO grade III and IV are poorly
differentiated and considered as high grade, with high grade
being more malignant and aggressive. Malignant gliomas are
among the most devastating and lethal cancers. Even with
state-of-the-art surgery, imaging, radiation, and chemother-
apy, the prognosis of high-grade gliomas is still poor, with a
two-year survival rate of less than 5% for WHO grade IV
astrocytoma (also known as glioblastoma multiforme (GBM))1
(1). The poor survival is primarily because of the recurrence of
tumor, which is resistant to standard therapies (2). Therefore,
new strategies to treat malignant gliomas are urgently
needed.
There is increasing evidence that a small population of
cancer stem cells (CSCs) within solid tumors is responsible for
tumor formation and ongoing growth (3–5). The existence of
CSCs has been demonstrated in GBMs (6–8). These CSCs
share similar properties with normal stem cells and have the
ability to self-renew, differentiate and drive tumorigenesis.
The CSCs are resistant to radiation therapy (9) and chemo-
therapy (10), and are considered to be the most likely cause of
cancer recurrence. It should be noted that recent findings
have shown the possibility of targeting CSCs for the treatment
of brain tumors (9, 11–21). Discovery of potential therapeutic
markers for GBM CSCs is thus of intense interest.
Tissue microarrays are a high-throughput proteomic tech-
nique for the identification of biomarkers by analyzing tens to
hundreds of tissue samples on a single slide (22, 23). Numer-
ous tissue samples from tissue microarrays are immunohis-
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tochemically analyzed at one time under the same histological
conditions, permitting high reproducibility between different
replicates of each sample and reliable comparison between
different samples. As the technique allows in situ visualization
of protein expression patterns, it is able to provide information
regarding subcellular location of target proteins.
Although CD133 has been identified as a marker for CSCs
in GBMs, the CD133 cells also have the capability to gen-
erate GBM-like tumors in immunodeficient nude mice or rats
(24–27). These studies suggest that CD133 is not necessar-
ily expressed in the CSCs in gliomas and there should be
more general and sensitive makers for CSCs in gliomas. Our
previous study (28) demonstrated that the expression level
of CD90 in a GBM-derived stem-like neurosphere line was
dramatically higher than that in three traditional adherent
GBM cell lines, indicating a role of CD90 as a potential
marker for CSCs in GBMs. CD90, also known as Thy-1, is a
heavily glycosylated, glycophosphatidylinositol (GPI)-an-
chored cell surface protein that has previously been identi-
fied as a marker for several kinds of stem cells such as
hematopoietic stem cells (29) and bone marrow-derived
mesenchymal stem cells (30). Recently, CD90 has also been
identified as a marker for liver CSCs (31). Based on these
observations, the potential of CD90 as a maker for glioma
CSCs was characterized in this study using glioma tissue
microarrays.
EXPERIMENTAL PROCEDURES
Tissue Samples—Tissue samples were provided in the form of
tissue microarrays (US Biomax, Inc. Rockville, MD USA Catalog No.
GL722 and GL807). Fifteen of the 58 samples had a GBM (age: 36 
17 years; 6 females and 9 males); 19 samples had a WHO grade III
astrocytoma (age: 46  11 years; 7 females and 12 males); 13
samples had a WHO grade II astrocytoma (age: 42  12 years; 5
females and 8 males); three samples had a WHO grade I astrocytoma
(age: 42 10 years; 1 females and 2 males); eight samples were from
normal subjects (age: 41  10 years; 4 females and 4 males). The
tissue samples were originated from different donors and each sam-
ple had at least two replicates. The glioma tissue sections are from
the tumor areas and do not include the adjacent normal tissues.
Immunohistochemical Analysis of Tissue Microarrays—Immunohis-
tochemical staining was performed using tissue microarrays. The
paraffin-embedded 5 m arrays were dewaxed in xylene for 10 min
and rehydrated through a series of alcohol solutions (100% ethanol
twice, 90% ethanol, 70% ethanol, 5 min each) to water. Antigen
retrieval was achieved by boiling the arrays in a citrate buffer at pH
6.0. Endogenous peroxidase activity was blocked using 6% H2O2.
The tissue microarrays were blocked with 2% normal goat serum and
incubated with rabbit antihuman CD90 monoclonal antibody (1:100
dilution, Abcam, Cambridge, MA) overnight at 4 °C. Immunodetection
was performed using the VECTASTAIN Elite ABC system (Vector
laboratories, Burlingame, CA) according to the manufacturer’s in-
structions. Hematoxylin counterstain was used to visualize nuclei. The
CD90 expression level in each tissue section was assessed in non-
necrotic areas of three separate microscopic fields of view under a
magnification of 20 and was represented by the mean of the per-
centage of CD90 cells.
Double Immunofluorescence Analysis of Tissue Microarrays—Ac-
cording to the different properties of each individual antibody, a
sequential procedure was used for the staining of CD90 and CD133,
whereas a simultaneous procedure was used for the staining of CD90
and CD31. Briefly, following deparaffinization, rehydration, antigen
retrieval, and endogenous peroxidase blocking of tissue microarrays,
double immunofluorescence staining for CD90 and CD133 was per-
formed with incubation of mouse anti-human CD133 monoclonal
antibody (1:5 dilution, Miltenyi Biotec, Auburn, CA) overnight at room
temperature, followed by anti-human CD90 (1:100 dilution) for 2 h at
room temperature. For double immunofluorescence staining of CD90
and CD31, a mixture of mouse anti-human CD31 (1:50 dilution, No-
vocastra, Newcastle Upon Tyne, UK) monoclonal antibody and anti-
human CD90 (1:100 dilution) was used to incubate with the arrays
overnight at 4 °C. DyLight 488 anti-rabbit IgG (HL) and DyLight 549
anti-mouse IgG (HL) (Vector laboratories, Burlingame, CA) were
used for immunofluorescence detection, and 4,6-diamidino-2-phe-
nylindole (DAPI) counterstain was used to visualize nuclear detail.
Cell Culture—The HSR-GBM1 neurosphere cells were maintained
in the NeuroCult proliferation medium (Stem Cell Technologies, Van-
couver, Canada) supplemented with 10 ng/ml EGF (PeproTech,
Rocky Hill, NJ), 10 ng/ml FGFb (PeproTech), and 2 g/ml heparin
(Sigma) as previously described (8, 12). Differentiation of the neuro-
spheres was achieved by plating 0.9–1  105 cells/cm2 on a poly-
ornithine (15 g/ml) coated culture plate and maintaining in the Neu-
roCult differentiation medium (Stem Cell Technologies, Vancouver,
BC, Canada) as described previously (8).
Cell Sorting and Limiting Dilution Assay of Sphere Formation—
Fluorescence-activated cell sorting experiments were carried out at
the Flow Cytometry Core at the University of Michigan. HSR-GBM1
neurospheres were dissociated into single cells and stained with
CD90-FITC (BD Biosciences, Lexington, KY; Cat# 555595) and
CD133-PE (Miltenyi Biotec, Auburn, CA; Cat# 130–080-801) antibod-
ies for FACS according to the manufactures’ instructions. Cells were
gated against isotype controls (IgG1-FITC and IgG1-PE for CD90 and
CD133, respectively) and analyzed for CD90, CD133, CD90/
CD133, CD90/CD133, and CD90/CD133 populations. Each
population of unsorted, CD90/CD133, CD90/CD133, and
CD90/CD133 cells was sorted into a 96-well plate. A twofold
dilution of single cells ranging from 125 to 0 was sorted directly into
each well of 96-well plates (repeated eight times) using a BDAria II
fluorescence-activated cell sorting machine for the limiting dilution
assay. Cells were incubated in the 96-wells for 6 days before exam-
ination of sphere formation. Percent of wells that did not form spheres
(y-axis) was plotted against the number of cells plated per well (x-
axis). The minimum number of cells required to form spheres was
calculated from the x-intercept of the graph.
Western Blotting—Western blotting was performed essentially as
described before (32). Briefly, 16 g of proteins from the undifferen-
tiated and differentiated HSR-GBM1 cells were separated by 4–20%
SDS-PAGE and transferred to polyvinylidene difluoride membranes
(Bio-Rad, CA). The membranes were blocked with 1% bovine serum
albumin in PBST (0.05% Tween-20 in PBS) for 2 h, and then incu-
bated with the following antibodies overnight at 4 °C: anti-CD90
(Abnova, Taipei, China), anti-CD133 (Abcam, Cambridge, MA), and
anti--actin (Abcam, Cambridge, MA). The membranes were washed
with PBST three times, incubated with peroxidase-conjugated IgG
(HL) for 1 h and washed another three times with PBST, followed by
detection with Supersignal West Pico Chemiluminescent horseradish
peroxidase Substrate (Thermo Scientific, IL).
Statistical Analysis—t test was used to compare the differences in
CD90 expression levels between different sample groups (i.e. astro-
cytoma WHO grade I, grade II, grade III, grade IV, and normal brains).
Statistical significance was defined as p  0.05.
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RESULTS
CD90 is a Marker for High-grade Gliomas—Expression lev-
els of CD90 were assessed immunohistochemically using
tissue microarrays containing 50 gliomas of different WHO
grades and eight normal subjects. Substantial differences in
CD90 staining were observed between high-grade and low-
grade gliomas. CD90 was not detectable in normal brains (Fig.
1A), WHO grade I astrocytomas (Fig. 1B), and most of WHO
grade II astrocytomas (Fig. 1C). In contrast, the expression of
CD90 was dramatically higher in WHO grade III astrocytomas
(Fig. 1D) and GBMs (Fig. 1E).
The CD90 expression level in each tissue section was semi-
quantitatively represented by the percentage of CD90 cells.
The relative CD90 expression levels in normal brains, WHO
grade I astrocytomas, WHO grade II astrocytomas, WHO
grade III astrocytomas and GBMs are shown in Fig. 2. All
normal brains and WHO grade I astrocytomas showed zero
CD90 levels. In patients with WHO grade II astrocytomas,
CD90 was either not detectable (10 of 13, 77%) or expressed
in less than 1% of cells (3 of 13, 23%). As to high-grade
gliomas, CD90 was detectable in all tested samples, with an
average CD90 level of 7% for WHO grade III astrocytomas
(range: 2.8–12.3%; n  19) and 9% for GBMs (range: 2.2–
18.9%; n  15). No significant difference in CD90 expression
was observed between grade I and grade II astrocytomas
(p  0.05), neither was there between grade III astrocytomas
and GBM (p  0.05). However, the expression levels of CD90
FIG. 1. Immunohistochemical stain-
ing for human CD90 in different
grades of astrocytomas and normal
brains. Paraffin-embedded tissue mi-
croarrays were stained using an anti-hu-
man CD90 antibody. CD90 was not de-
tected in normal brain (A), astrocytoma
WHO grade I (B) and diffuse astrocy-
toma WHO grade II (C). In contrast,
moderate or strong staining for CD90
was observed in anaplastic astrocy-
toma WHO grade III (D) and GBM WHO
grade IV (E). Hematoxylin counterstain
was used to visualize nuclei. Scale bar,
100 m.
FIG. 2. Scatter plot of CD90 expression levels in n  50 patients
with different grades of astrocytomas and n  8 normal subjects.
The CD90 expression level of each tissue sample was represented by
the percentage of CD90 cells. Each point corresponds to the CD90
expression level of a single sample. CD90 expression levels were
significantly elevated in patients with high-grade astrocytomas (WHO
grade III and IV). Astro 1 represents astrocytoma WHO grade I; Astro
2 represents diffuse astrocytoma (WHO grade II); Astro 3 represents
anaplastic astrocytoma (WHO grade III); GBM represents glioblas-
toma multiforme (WHO grade IV).
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in high-grade gliomas were significantly higher than in low-
grade gliomas (p 0.0001). As CD90 was highly expressed in
high-grade gliomas but it was almost not expressed in low-
grade gliomas and normal brains, CD90 may serve as a
marker for high-grade gliomas.
CD90 Cells Contain a Subpopulation of CD133 Cells in
GBM—To determine whether the CD90 cells were also ex-
pressing the GBM stem cell marker CD133, we performed
double immunofluorescence staining for CD90 and CD133 in
primary GBM tissue sections. CD90 and CD133 were co-
expressed in GBM, where 100% of the CD133 cells were
also positive for CD90, but only a small part of CD90 cells
were positive for CD133 (Fig. 3). This indicates that the
CD133 stem-like cells are a subpopulation of CD90 cells in
GBMs in vivo.
We also tested the expression of CD90 and CD133 in a
GBM-derived stem-like neurosphere line HSR-GBM1 which
has been extensively used in CSC studies before (8, 12, 15,
28, 33). Flow cytometry analysis showed that CD90 was ex-
pressed in more than 99% of HSR-GBM1 cells (Fig. 4A),
whereas CD133 was expressed in 80% of HSR-GBM1 cells
(Fig. 4B). A flow cytometry dot plot showed that 99.99%
(79.72%/(79.72%  0.01%)) of CD133 cells were also ex-
pressing CD90, while 79.94% (79.72%/(79.72%  20.01%))
of CD90 cells were expressing CD133 (Fig. 4C). The flow
cytometry analysis demonstrated that CD133 cells were a
subpopulation of CD90 cells in GBM-derived stem-like
neurospheres.
CD90 is a New Marker for GBM Stem Cells—To determine
whether CD90 is a GBM CSC marker, we induced the undif-
ferentiated HSR-GBM1 stem-like neurospheres to differenti-
ate them and then analyzed the alteration of CD90 level during
the differentiation process. We and others have found that
most of stem-like cells were lost after differentiation of HSR-
FIG. 3. Double immunofluorescence
staining for CD90 and CD133 in a GBM
section. CD90 cells contain a subpop-
ulation of CD133 cells, where the
CD90CD133 cells are shown in yellow
in the merged image. DAPI counterstain
was used to visualize nuclei. As a nega-
tive control, a WHO grade II astrocytoma
was double stained for CD90 and CD133
(data shown in supplemental Fig. S2).
Scale bar, 100 m.
FIG. 4. Flow cytometry analysis of the expression of CD90 and CD133 in the stem-like neurosphere HSR-GBM1. Flow cytometry
histograms showed more than 99% of HSR-GBM1 cells were CD90-positive (A) and about 80% were CD133 positive (B). C, In the flow
cytometry dot plot, the HSR-GBM1 cells were classified into four cell populations based on the expression of CD90 and CD133. The
percentage of each subpopulation was shown. FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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GBM1 cells, as indicated by the reduced expression of the
known GBM stem cell marker CD133 (15, 33, 34). Western
blotting analysis showed that CD90 was dramatically down-
regulated in the differentiated cells compared with the undif-
ferentiated stem-like cells, with a similar differential expres-
sion pattern to CD133 (Fig. 5A). These results suggest that
both CD90 and CD133 levels were decreased along with the
loss of stem-like cells, and CD90 may represent a new marker
for CSCs in GBM.
We further performed a limiting dilution assay to evaluate
the self-renewal ability of the CD90 cells. As a result, the
CD90/CD133, CD90/CD133, and unsorted populations
of GBM neurospheres required a similar number of cells to
form spheres (Figs. 5B and 5C). Compared with them, the
CD90/CD133 population required more than 2-fold of cells
to form spheres. This experiment demonstrated that the
CD90 cells had much higher potential of stemness than the
CD90 cells, which confirmed that CD90 was a marker for
GBM CSCs.
CD90 Cells are Clustered Around Tumor Vasculatures in
Gliomas—As shown in Figs. 1D and 1E, the CD90 cells
formed vascular-like structures in high-grade gliomas. To test
the possible localization of CD90 cells in tumor vasculature
in gliomas, we performed double immunofluorescence stain-
ing for CD90 (Fig. 6A) and a vascular endothelial cell marker
CD31 (Fig. 6B) in GBMs. The merged images showed that
CD90 was either colocalized with CD31 (shown in yellow) or
near CD31 (shown in green) in the tumor vasculature struc-
tures in GBM (Figs. 6D and 6E). We evaluated the double
staining of CD90 and CD133 using 7 GBM tissue samples on
a tissue microarray slide (US Biomax Catalog No. GL722). The
staining results are reproducible in all the 7 GBM tissue mi-
croarrays on the slide (supplemental Fig. S1). These results
suggest that CD90 GBM CSCs may reside within the endo-
thelial niche for their self-renewal, consistent with our recent
finding that endothelial cells create a stem cell niche in glio-
blastoma by providing Notch ligands that nurture self-renewal
of cancer stem-like cells (15).
DISCUSSION
In this study, we applied tissue microarrays to analyze the
expression of CD90 in different grades of glioma tissues and
found that the CD90 levels in high-grade gliomas (WHO grade
III and IV) were significantly higher than in low-grade gliomas
(WHO grade I and II) and normal brains (Fig. 1 and Fig. 2).
These observations suggest that the CD90 expression level
may be an indicator of the aggressiveness of gliomas. CD90
showed high sensitivity and specificity as a marker, with high
or medium expression levels in all the tested high-grade gli-
oma tissues but barely detectable in low-grade gliomas and
FIG. 5. CD90 is a marker for GBM stem cells. A, Differential expression of CD90 and CD133 along with the differentiation of the stem-like
HSR-GBM1 neurospheres. When the stem-like neurospheres were forced to differentiate, both CD90 and CD133 expression levels were
dramatically reduced. Stem-like represents the stem-like HSR-GBM1 neurospheres, which are undifferentiated cells; Diff represents the
differentiated HSR-GBM1 cells. B, Populations of unsorted, CD90/CD133, CD90/CD133, and CD90/CD133 HSR-GBM1 neurospheres
were analyzed for their ability of sphere formation by the limiting dilution assay. y-axis: percent of wells that did not form spheres; x-axis: the
number of cells plated per well. C, The minimum number of cells required to form spheres for each population of HSR-GBM1 neurospheres.
The number was similar between the unsorted, CD90/CD133 and CD90/CD133 populations. Compared with these populations, the
CD90/CD133 population required the most number of cells (more than twofold) to form spheres.
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normal brains. Therefore, CD90 appears to be a promising
new prognostic marker for gliomas.
It should be noted that in contrast to the highly differenti-
ated low-grade gliomas, GBMs are undifferentiated and
therefore are more likely to contain undifferentiated CSCs.
Because the expression level of CD90 is dramatically in-
creased in GBMs compared with low-grade gliomas, CD90
can be a new marker of these CSCs within GBM tissues.
CD90 has been identified as a marker for hematopoietic
stem cells (29), bone marrow-derived mesenchymal stem
cells (30), hepatic stem cells (35), as well as liver CSCs (31).
Although we and others have also observed the expression of
CD90 in GBM-derived stem cells (10, 28), the potential of
CD90 as a marker for these in vitro cultured stem cells and
CSCs in primary glioma tissues remains uncharacterized. To
the best of our knowledge, this work is the first to address this
issue. In this study, the double immunofluorescence staining
of GBM tissues (Fig. 3) and flow cytometry analysis of GBM-
derived stem-like neurospheres (Fig. 4) revealed that CD133
stem cells are a subpopulation of CD90 cells in GBMs in vivo
and in vitro. The expression levels of both CD90 and CD133
were reduced along with the loss of stem cells after differen-
tiation (Fig. 5A). Further a limiting dilution assay demonstrated
that the CD90/CD133 and CD90/CD133 populations of
GBM neurospheres had comparable ability to form spheres,
whereas the CD90/CD133 population showed much lower
potential of stemness (Figs. 5B and 5C). These findings sug-
gest that CD90 is a novel marker for CSCs in high-grade
gliomas and it is a more general marker than CD133.
Interestingly, we observed the formation of vascular-like
structures by CD90 cells in high-grade gliomas (Fig. 1). This
indicates that CD90 cells may reside within the endothelial
niche to self-renew (15). There has been increasing evidence
that stem-like cells within GBMs are able to generate tumor
vasculature by endothelial cell differentiation (36, 37), which
represents a new mechanism of tumor angiogenesis. In this
study, dual staining with CD90 and a vascular endothelial cell
marker CD31 confirmed that CD90 cells were clustered
around the tumor vasculatures in GBMs (Fig. 6). These data
suggest that the GBM-derived CD90 stem cells may have
the potential to differentiate into vascular endothelial cells.
Our findings may have the following therapeutic implica-
tions. First, CD90 is a CSC marker that is more sensitive than
CD133, which makes it an ideal drug target for cancer stem
cell-based therapies of malignant gliomas. Second, the find-
ing that CD90 cancer stem cells may play a critical role in the
formation of tumor vasculature implies that CD90 may be a
good target for anti-angiogenesis treatment of gliomas.
FIG. 6. Double immunofluorescence
staining for CD90 and CD31 in GBM. A
GBM section was stained with anti-
CD90 (A) and anti-CD31 (B). DAPI coun-
terstain (C) was used to visualize nuclei.
Colocalization of CD90 and CD31 was
observed in the merged image (D). An
area of this merged image was selected
and a higher magnification image of
the area was also shown (E). Scale bar in
A–D, 100 m; Scale bar in E, 50 m.
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In conclusion, we have shown that CD90 can be used to
distinguish high-grade gliomas from low-grade gliomas and
normal brains. Further study reveals that CD90 is a new
marker for CSCs in high-grade gliomas and it is more general
than the known stem cell marker CD133. The CD90 cells
form vascular-like structures and partially co-localize with an
endothelial marker CD31 in high-grade glioma tissues, sug-
gesting that CD90 cells may also reside within the endothe-
lial niche to self-renew. It is also possible that CD90 cells
generate tumor vasculature via differentiation into endothelial
cells. These findings provide new insights into the cancer
stem cell biology of gliomas.
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